Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the association between diagnosis of Parkinson disease (PD) and risk factors or early symptoms amenable to population‐based screening. Methods: A systematic review and meta‐analysis of risk factors for PD. Results: The strongest associations with later diagnosis of PD were found for having a first‐degree or any relative with PD (odds ratio [OR], 3.23; 95% confidence interval [CI], 2.65–3.93 and OR, 4.45; 95% CI, 3.39–5.83) or any relative with tremor (OR, 2.74; 95% CI, 2.10–3.57), constipation (relative risk [RR], 2.34; 95% CI, 1.55–3.53), or lack of smoking history (current vs never: RR, 0.44; 95% CI, 0.39–0.50), each at least doubling the risk of PD. Further positive significant associations were found for history of anxiety or depression, pesticide exposure, head injury, rural living, beta‐blockers, farming occupation, and well‐water drinking, and negative significant associations were found for coffee drinking, hypertension, nonsteroidal anti‐inflammatory drugs, calcium channel blockers, and alcohol, but not for diabetes mellitus, cancer, oral contraceptive pill use, surgical menopause, hormone replacement therapy, statins, acetaminophen/paracetamol, aspirin, tea drinking, history of general anesthesia, or gastric ulcers. In the systematic review, additional associations included negative associations with raised serum urate, and single studies or studies with conflicting results. Interpretation: The strongest risk factors associated with later PD diagnosis are having a family history of PD or tremor, a history of constipation, and lack of smoking history. Further factors also but less strongly contribute to risk of PD diagnosis or, as some premotor symptoms, require further standardized studies to demonstrate the magnitude of risk associated with them. ANN NEUROL 2012
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
(2014) · Medical Entomology and Zoology · Cited by 17,633
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099 · cited 1×
“Publication bias was assessed using the Egger test, and where statistically significant bias was found, the trim and fill method was used to adjust for it.(28,29) Where data were not given in a way”
MethodStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Both constipation and mood disorders have been suggested to correlate with brainstem involvement that, together with olfactory bulb involvement, occurs early in PD and later spreads to the substantia nigra and to the cortex.(41) This theory would also support a role for hyposmia, erectile dysfunction, and excessive da…”
BackgroundDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
RetractedColonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
“Intestinal bacteria may play a role in PD intestinal symptoms, such as constipation and bloating.(51-55)”
BackgroundMDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,309
Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159
The genetic architecture of Parkinson's disease
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30287-x · Cited by 1,114
The epidemiology of Parkinson's disease
Ben-Shlomo, Y., Darweesh, S., Llibre-Guerra, J., Marras, C., San Luciano, M., & Tanner, C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01419-8 · Cited by 967
Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes
Poole, R., Kennedy, O. J., Roderick, P., Fallowfield, J. A., Hayes, P. C., & Parkes, J. (2017) · BMJ · doi:10.1136/bmj.j5024 · Cited by 835
Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study
Schrag, A., Horsfall, L., Walters, K., Noyce, A., & Petersen, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70287-x · Cited by 674
Self-citationAlternatively activated microglia and macrophages in the central nervous system
Franco, R., & Fernández-Suárez, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.003 · Cited by 650
Su, D., Cui, Y., He, C., Yin, P., Bai, R., Zhu, J., Lam, J. S. T., Zhang, J., Yan, R., Zheng, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-080952 · Cited by 611
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Analysis of Gut Microbiota in Patients with Parkinson’s Disease
Petrov, V. A., Saltykova, I. V., Zhukova, I. A., Alifirova, V. M., Zhukova, N. G., Dorofeeva, Y. B., Tyakht, A. V., Kovarsky, B. A., Alekseev, D. G., Kostryukova, E. S., et al. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3700-7 · Cited by 487
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Environmental Toxins and Parkinson's Disease
Goldman, S. M. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135937 · Cited by 505
LRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses
Bellou, V., Belbasis, L., Tzoulaki, I., Evangelou, E., & Ioannidis, J. P. A. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.12.008 · Cited by 426
Genetics and Pathogenesis of Parkinson's Syndrome
Ye, H., Robak, L. A., Yu, M., Cykowski, M., & Shulman, J. M. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-034145 · Cited by 416
Advances in markers of prodromal Parkinson disease
Postuma, R. B., & Berg, D. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.152 · Cited by 405
Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate?
Doty, R. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30123-0 · Cited by 405
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J., & Singleton, A. B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104782 · Cited by 370
The impact of coffee on health
Cano-Marquina, A., Tarín, J. J., & Cano, A. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.02.002 · Cited by 321
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Ramesh, S., & Arachchige, A. S. P. M. (2023) · AIMS Neuroscience · doi:10.3934/neuroscience.2023017 · Cited by 289
The Concept of Prodromal Parkinson’s Disease
Mahlknecht, P., Seppi, K., & Poewe, W. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150685 · Cited by 288
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
“…have provided positive results in preclinical models; however epidemiological studies have yielded conflicting results on the extent to which chronic intake of these drugs reduce the risk of PD (Bower et al., 2006; Chen et al., 2005; Esposito et al., 2007; Gao et al., 2011b; Noyce et al., 2012).”
ResultMitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects
Borsche, M., Pereira, S. L., Klein, C., & Grünewald, A. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-201981 · Cited by 275
Organophosphate pesticide exposure and neurodegeneration
Sánchez-Santed, F., Colomina, M. T., & Herrero Hernández, E. (2016) · Cortex · doi:10.1016/j.cortex.2015.10.003 · Cited by 257
Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study
Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., & Hirayama, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187307 · Cited by 248
Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study
De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T. (2018) · Neurology · doi:10.1212/wnl.0000000000005771 · Cited by 242
“An association between diabetes mellitus and future risk of Parkinson disease (PD) has been postulated although evidence remains equivocal.(1,2) Cohort studies have shown conflicting results, but a meta-analysis reported an increased pooled relative risk of developing PD after diabetes mellitus.”
ResultSelf-citationBreckenridge, C. B., Berry, C., Chang, E. T., Sielken, R. L., & Mandel, J. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151841 · Cited by 239
“Our meta-analysis results for cigarette smoking are comparable to those reported by others (Table 6; [37, 39, 40]).”
BackgroundResultInfluentialType 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression
Chohan, H., Senkevich, K., Patel, R. K., Bestwick, J. P., Jacobs, B. M., Bandres Ciga, S., Gan‐Or, Z., & Noyce, A. J. (2021) · Movement Disorders · doi:10.1002/mds.28551 · Cited by 228
“Treating T2DM may slow down the progression of PD.”
BackgroundSelf-citationConstipation preceding Parkinson's disease: a systematic review and meta-analysis
Adams-Carr, K. L., Bestwick, J. P., Shribman, S., Lees, A., Schrag, A., & Noyce, A. J. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311680 · Cited by 228
Self-citationMeta-analyses on prevalence of selected Parkinson's nonmotor symptoms before and after diagnosis
Chen, H., Zhao, E. J., Zhang, W., Lu, Y., Liu, R., Huang, X., Ciesielski-Jones, A. J., Justice, M. A., Cousins, D. S., & Peddada, S. (2015) · Translational Neurodegeneration · doi:10.1186/2047-9158-4-1 · Cited by 212
“A previous meta-analysis examined NMS and other factors in relation to PD risk [24]; however, it provided no data on symptom prevalence.”
MethodM1 and M2 immune activation in Parkinson’s Disease: Foe and ally?
Moehle, M. S., & West, A. B. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.018 · Cited by 200
Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism
Borsche, M., König, I. R., Delcambre, S., Petrucci, S., Balck, A., Brüggemann, N., Zimprich, A., Wasner, K., Pereira, S. L., Avenali, M., et al. (2020) · Brain · doi:10.1093/brain/awaa246 · Cited by 196
“These studies are in keeping with the epidemiological observation that intake of anti-inflammatory drugs lowers the risk of developing Parkinson’s disease (Noyce et al., 2012).”
ResultOutside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
“For instance, an association has been shown between the abundance of specific gut bacteria and PD development (177), where patients with PD have a decrease in the number of intestinal bacteria that are capable of producing SCFA.”
BackgroundMany faces of Parkinson's disease: non-motor symptoms of Parkinson's disease
Lee, H. M., & Koh, S.-B. (2015) · Journal of Movement Disorders · doi:10.14802/jmd.15003 · Cited by 191
Rotenone-Induced Model of Parkinson’s Disease: Beyond Mitochondrial Complex I Inhibition
Ibarra-Gutiérrez, M. T., Serrano-García, N., & Orozco-Ibarra, M. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03193-8 · Cited by 165
Mertsalmi, T. H., Aho, V. T. E., Pereira, P. A. B., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2017) · European Journal of Neurology · doi:10.1111/ene.13398 · Cited by 153
Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
Postuma, R. B., Anang, J., Pelletier, A., Joseph, L., Moscovich, M., Grimes, D., Furtado, S., Munhoz, R. P., Appel-Cresswell, S., Moro, A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004568 · Cited by 135
Liu, Y., Xin, H., Zhang, Y., Che, F., Shen, N., & Cui, Y. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115645 · Cited by 123
In vivo gastric detection of α-synuclein inclusions in Parkinson's disease
Sánchez‐Ferro, Á., Rábano, A., Catalán, M. J., Rodríguez‐Valcárcel, F. C., Díez, S. F., Herreros‐Rodríguez, J., García‐Cobos, E., Álvarez‐Santullano, M. M., López‐Manzanares, L., Mosqueira, A. J., et al. (2015) · Movement Disorders · doi:10.1002/mds.25988 · Cited by 123
Baldacci, F., Lista, S., Cavedo, E., Bonuccelli, U., & Hampel, H. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304217 · Cited by 113
Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?
Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N., & Fakhoury-Sayegh, N. (2019) · Nutrients · doi:10.3390/nu11081896 · Cited by 109
Huang, H.-K., Wang, J.-H., Lei, W.-Y., Chen, C.-L., Chang, C.-Y., & Liou, L.-S. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.11.331 · Cited by 106
Lamotte, G., Rafferty, M. R., Prodoehl, J., Kohrt, W. M., Comella, C. L., Simuni, T., & Corcos, D. M. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140425 · Cited by 98
Mihaila, D., Donegan, J., Barns, S., LaRocca, D., Du, Q., Zheng, D., Vidal, M., Neville, C., Uhlig, R., & Middleton, F. A. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218252 · Cited by 94
Antibiotic Exposure and Risk of Parkinson's Disease in Finland: A Nationwide Case‐Control Study
Mertsalmi, T. H., Pekkonen, E., & Scheperjans, F. (2020) · Movement Disorders · doi:10.1002/mds.27924 · Cited by 88
Azizova, T. V., Bannikova, M. V., Grigoryeva, E. S., Rybkina, V. L., & Hamada, N. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyz230 · Cited by 93
Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease
Jensen, M. P., Jacobs, B. M., Dobson, R., Bandres‐Ciga, S., Blauwendraat, C., Schrag, A., Noyce, A. J., & The International Parkinson's Disease Genomics Consortium (IPDGC) (2021) · Annals of Neurology · doi:10.1002/ana.26034 · Cited by 91
“penetrance of LRRK2 variants with use of immunosuppressants and nonsteroidal anti-inflammatory drugs.(15,16)”
BackgroundSelf-citationNicotinic acetylcholine receptors in neurological and psychiatric diseases
Terry, A. V., Jones, K., & Bertrand, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106764 · Cited by 90
Kumaran, R., & Cookson, M. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv236 · Cited by 86
“) in PD (54) whereas the prolonged use of ibuprofen, a non-steroidal anti-inflammatory drug, has been suggested to lower the risk of developing PD (55).”
BackgroundResearch on the Premotor Symptoms of Parkinson’s Disease: Clinical and Etiological Implications
Chen, H., Burton, E. A., Ross, G. W., Huang, X., Savica, R., Abbott, R. D., Ascherio, A., Caviness, J. N., Gao, X., Gray, K. A., et al. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1306967 · Cited by 83
“A recent meta-analysis also confirmed that constipation and mood disorders were associated with higher risk of PD (Noyce et al. 2012).”
ResultLinking Smoking, Coffee, Urate, and Parkinson’s Disease – A Role for Gut Microbiota?
Scheperjans, F., Pekkonen, E., Kaakkola, S., & Auvinen, P. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150557 · Cited by 83
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans
Scott, G. D., Lim, M. M., Drake, M. G., Woltjer, R., & Quinn, J. F. (2021) · Movement Disorders · doi:10.1002/mds.28636 · Cited by 42
“Outside of retrospective diagnostic coding, additional caveats with the current study include under-correction for certain confounders, particularly female gender, in the predominately male Veteran cohort,(39) and absence of ancillary studies (eg, imaging, functional studies, discrete laboratory data), which can furth…”
Kulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-230206 · Cited by 40
“The association of pesticides exposure and risk of PD is well known [10, 15, 16], being included as an independent risk factor for PD in the original and updated version of the International Parkinson and Movement Disorders Society (MDS) research criteria for prodromal PD (positive likelihood ratio…”
BackgroundMoist smokeless tobacco (Snus) use and risk of Parkinson’s disease
Yang, F., Pedersen, N. L., Ye, W., Liu, Z., Norberg, M., Forsgren, L., Trolle Lagerros, Y., Bellocco, R., Alfredsson, L., Knutsson, A., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw294 · Cited by 34
ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson’s Disease
Siokas, V., Aloizou, A.-M., Tsouris, Z., Liampas, I., Liakos, P., Calina, D., Docea, A. O., Tsatsakis, A., Bogdanos, D. P., Hadjigeorgiou, G. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030381 · Cited by 29
Watanabe, Y., & Watanabe, T. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0327-y · Cited by 31
“For PD, some meta-analyses reported that the history of head injuries 20 is a risk factor for the disease [23,54,55]; however, a recent large-scale case-control study could not 21”
Common signatures of differential microRNA expression in Parkinson’s and Alzheimer’s disease brains
Dobricic, V., Schilling, M., Farkas, I., Gveric, D. O., Ohlei, O., Schulz, J., Middleton, L., Gentleman, S. M., Parkkinen, L., Bertram, L., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac274 · Cited by 22
Genetic risk of Parkinson’s disease in the general population
Darweesh, S. K. L., Verlinden, V. J. A., Adams, H. H. H., Uitterlinden, A. G., Hofman, A., Stricker, B. H., van Duijn, C. M., Koudstaal, P. J., & Ikram, M. A. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.05.030 · Cited by 13
Metadata
- Authors
- Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-10-15
- Volume
- 72
- Issue
- 6
- Pages
- 893-901
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1993790483
- Cited by
- 778
- References
- 59
- FWCI
- 25.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.